APIs for research and impurities

1-Phenyl-1,2,3,4-tetrahydro-isoquinoline is a synthetic compound which has been used as a lead compound for the development of drugs with dopamine β-hydroxylase inhibitory activity. In vitro studies have shown that 1-phenyl-1,2,3,4-tetrahydro-isoquinoline inhibits human serum dopamine β-hydroxylase and can be used to study the possible role of this enzyme in Parkinson's disease. This drug is racemized in the body and has been found to be effective against Parkinson's disease in rats. It is also an enantiomer that has industrial applications for the production of polyurethane foam insulation coatings.

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

Fonofos is a potent inhibitor that has been shown to induce apoptosis in Chinese hamster ovary cells. It is also known to inhibit chitin kinase, a protein that plays an important role in the biosynthesis of chitin, which is essential for the formation of cell walls in fungi and insects. Fonofos has medicinal properties and has been studied as a potential anticancer agent due to its ability to inhibit tumor growth. In vitro studies have shown that Fonofos can inhibit the growth of human cancer cells by inhibiting heparin-binding proteins. Additionally, it has been found to have inhibitory effects on several other enzymes involved in cancer development and progression. Although not approved for use in humans, Fonofos may hold promise as a therapeutic agent for the treatment of certain cancers.

Pirtenidine is a potent and selective kinase inhibitor that has been shown to inhibit the activity of cyclin-dependent kinases. It has demonstrated promising results in preclinical studies as an anticancer agent, inducing apoptosis in cancer cells. Pirtenidine is an analog of protein kinase inhibitors, which have been used to treat various types of tumors. It has been found to be effective against human cancer cell lines and has shown significant tumor growth inhibition in animal models. Pirtenidine has also been reported to be a potent urine inhibitor of Chinese hamster ovary cells, making it a promising candidate for the treatment of urinary tract cancers.

Please enquire for more information about Acrolein-d4 including the price, delivery time and more detailed product information at the technical inquiry form on this page

4-(Phthalazin-1-yloxy)aniline is an analog of cyclin-dependent kinase (CDK) inhibitors that has shown promising anticancer activity. It inhibits the activity of CDKs, which are enzymes involved in regulating cell division and proliferation. This compound has been tested on Chinese hamster ovary cells and has demonstrated potent antiproliferative activity against various cancer cell lines. 4-(Phthalazin-1-yloxy)aniline induces apoptosis in tumor cells, leading to their death. This compound may be a potential candidate for the development of novel anticancer drugs that target CDKs and promote tumor cell death. Additionally, this compound can be detected in urine samples, making it a useful biomarker for cancer diagnosis and monitoring.

Simvastatin acid is the active form of simvastatin, a drug used to lower blood cholesterol levels. Simvastatin acid inhibits HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. This conversion is a rate-limiting step in the synthesis of cholesterol and other lipids. Simvastatin acid binds to polymerase chain and drug transporter proteins, which leads to cell lysis. The concentration–time curve for simvastatin acid is linear and the half-life is approximately 12 hours. When simvastatin acid is administered with drugs that are potent inducers of CYP3A4 or UGT1A1 enzymes, there may be an increased risk for drug interactions. Simvastatin acid has shown no significant human pharmacokinetic interactions with food or grapefruit juice at doses up to 200 mg/day. There are limited data on the pharmacokinetics of simvastatin